Lake Street initiated coverage of TriSalus Life Sciences (TLSI) with a Buy rating and $10 price target TriSalus is commercializing its pressure-enabled drug-delivery device, TriNav, to treat liver cancer and the device offers “a win-win-win for patients, payors, and physicians” compared to traditional end-hole catheters. The firm thinks TriSalus can eventually build a multi-$100M business in its initial $450M-plus liver cancer market noting that its current market share percentage is in the mid-single digits.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
- TriSalus Life Sciences sees Q4 revenue $8.3M, consensus $8.04M
- TriSalus Life Sciences announces publication of pre-clinical data
- TriSalus Announces Leadership Changes and New Incentive Program
- Roth expects ‘continued strong execution’ from TriSalus under new CFO
- Roth expects ‘continued strong execution’ TriSalus under new CFO